Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

MLA

Alan Menter, et al. “Risankizumab: An Anti-IL-23 Antibody for the Treatment of Psoriasis.” Drug Design, Development and Therapy, vol. 12, Nov. 2018, pp. 3879–83. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....57172c1abf1e01d09bb7fe84c7e6bcd8&authtype=sso&custid=ns315887.

APA

Alan Menter, Dario Kivelevitch, Allie K Preston, & Isabel Haugh. (2018). Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Design, Development and Therapy, 12, 3879–3883.

Chicago

Alan Menter, Dario Kivelevitch, Allie K Preston, and Isabel Haugh. 2018. “Risankizumab: An Anti-IL-23 Antibody for the Treatment of Psoriasis.” Drug Design, Development and Therapy 12 (November): 3879–83. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....57172c1abf1e01d09bb7fe84c7e6bcd8&authtype=sso&custid=ns315887.